Youcare Pharmaceutical (SH:688658) Xin Lang Cai Jing·2025-09-01 03:18Core Viewpoint - Yuyuan Pharmaceutical experienced a 5.16% increase in stock price, reaching 28.95 CNY per share, with a trading volume of 1.59 billion CNY and a market capitalization of 13.028 billion CNY [1] Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. is located in Beijing Economic and Technological Development Zone and was established on August 14, 2001, with its listing date on December 24, 2020 [1] - The company focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - Key products contributing significantly to revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] - The revenue composition is as follows: cardiovascular drugs 55.67%, anti-infection 20.88%, raw materials 8.73%, digestive system 6.87%, diabetes 4.85%, others 2.62%, and technical services 0.02% [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) is among the top ten circulating shareholders of Yuyuan Pharmaceutical, holding 7.2677 million shares, unchanged from the previous period, representing 1.62% of circulating shares [2] - The fund has achieved a year-to-date return of 51.91%, ranking 599 out of 8254 in its category, and a one-year return of 48.77%, ranking 2666 out of 8037 [2] Fund Management - The fund manager of Southern Medical Health Flexible Allocation Mixed A is Wang Zhengjiao, who has been in the position for 7 years and 39 days, managing a total fund size of 2.417 billion CNY [3] - During Wang's tenure, the best fund return was 70.35%, while the worst was -53.83% [3] Fund Holdings - Southern Medical Health Flexible Allocation Mixed A Fund holds 7.2677 million shares of Yuyuan Pharmaceutical, unchanged from the previous period, making it the third-largest holding in the fund, accounting for 5.72% of the fund's net value [4]